0,1,2,3,4,5
"Viruses 2014, 6",,,,,2400
,,Table 3. Cont.,,,
Target,Gene,Vector/Delivery,Immunization,Response,Reference
,IL-12,SFV/Particles,Mouse,Tumor eradication,[96]
,,SFV/Encapsulated,,5-fold IL-12,
,IL-12,,Human Phase I,,[95]
,,particles,,expression,
,MUC18/MCAM,SIN/DNA,Mouse,Tumor protection,[97]
,,,,"CEA Abs, extended",
Metastatic,CEA,VEE/Particles,Human Phase I,,[98]
,,,,survival,
,PSMA,VEE/Particles,Human Phase I,PSMA Abs,[99]
Prostate cancer,PSMA,VEE/Particles,Mouse,Tumor response,[100]
,STEAP,VEE/DNA,Mouse,Anti-tumor response,[101]
,PSCA,VEE/Particles,Mouse,Tumor protection,[102]
Tumor,Î²-galactosidase,SFV/RNA,Mouse,Tumor protection,[74]
,IL-12,SFV/Particles,Mouse,Tumor protection,[103]
Tumor antigen,MHC class II,SFV/Particles-DNA,Mouse,Immunogenicity,[104]
,,,,"CTL, tumor",
,P815,SFV/Particles,Mouse,,[105]
,,,,protection,
,trp-1,SIN/DNA,Mouse,Antitumor activity,[91]
,"Abbreviations: CEA, carcinoembryonic antigen; CRT, calreticulin; CTL, cytotoxic T-lymphocyte activity; DCs, dendritic",,,,
